top of page

"An Update from Duke Health October 29, 2021

After careful review and thoughtful deliberation, Duke Health has decided it will not provide aducanumab for the treatment of Alzheimer’s disease at this time..."

Aducanumab: look before leaping

"How did this happen? The rationale for testing a drug that enhances clearance of amyloid-β comes from the identification of rare mutations that enhance deposition of amyloid-β in the brain that is associated with early-onset AD; the finding that enhanced clearance of amyloid-β in mouse models with these gene defects improves behavioral outcomes; and evidence that people with sporadic or genetic AD have abnormal deposition of amyloid-β in the brain many years prior to dementia ..."

Robert Wang, Ph.D., M.D. | Private Practice


"The studies have shown there is no meaningful signal for clinical benefit with aducanumab. Instead, the signal is for amyloid removal. Yet the studies for aducanumab and for prior synthetic amyloid removing antibodies have demonstrated no significant clinical benefit with a sizeable group of recipients developing mild to severe ARIA leading to accelerated functional decline."
 

Accelerated Approval Program

F.D.A. Panel Declines to Endorse Controversial Alzheimer’s Drug

Alzheimer's drug approved despite doubts

Leqembi can cause serious side effects, including:

Improved Alzheimer's - Firecracker

Recipes are examples, and for future research.

 

bottom of page